4D Molecular Therapeutics, Inc.
FDMT · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.12 | 0.45 | -0.25 | -0.53 |
| FCF Yield | -46.05% | -9.91% | -13.67% | -12.86% |
| EV / EBITDA | -0.97 | -5.14 | -6.34 | -6.76 |
| Quality | ||||
| ROIC | -34.99% | -34.83% | -44.23% | -21.08% |
| Gross Margin | 100.00% | -368.54% | -2,464.81% | -240.17% |
| Cash Conversion Ratio | 0.84 | 0.75 | 0.81 | 0.97 |
| Growth | ||||
| Revenue 3-Year CAGR | -77.22% | 4.73% | -38.74% | 2,622,484.32% |
| Free Cash Flow Growth | -76.13% | 20.01% | -25.53% | -50.73% |
| Safety | ||||
| Net Debt / EBITDA | 0.69 | 2.16 | 0.34 | 1.96 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | -13.21 | 66.55 | -27.39 |